002007.SZHualan Biological Engineering Inc.
The schedule
- Mon2Nov
Estimated announcement for Q3, historically the company's strongest quarter due to peak seasonal vaccine sales recognition.
- Fri15Jan
Expected early-year regulatory update by China's National Health Commission regarding plasma collection station quotas and broader healthcare cost containment measures.
- Mon26Apr
Full-year 2026 results release, offering comprehensive guidance for 2027 and updates on pipeline commercialization.
Past
- Tue22Sep
Actual outcome: Bull · $13.31 at outcome
Price reached or exceeded bull target ($13.30) at outcome date.
China's National Medical Products Administration typically publishes peak batch release data for quadrivalent influenza vaccines, a core revenue driver for Hualan.
- Fri28Aug
Actual outcome: Bear · $12.80 at outcome
Price reached or fell below bear floor ($12.50) at outcome date.
Estimated release of first-half 2026 financial results, capturing the ongoing impact of volume-based procurement (VBP) and baseline normalization on blood products.
